QCM Cayman’s Biogen BIIB Stock Holding History

QCM Cayman’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,700	Closed	-$1.5M	–	231
2015 Q2	$1.5M	Buy	+3,700	New	+$1.48M	0.57%	33
2014 Q2	–	Sell	-4,600	Closed	-$1.41M	–	244
2014 Q1	$1.41M	Buy	4,600 +3,300	+254%	+$1.05M	0.31%	45
2013 Q4	$363K	Buy	+1,300	New	+$336K	0.12%	66

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QCM Cayman's BIIB Position: Q1 2021 in Review

QCM Cayman sold out of Biogen (BIIB) in Q1 2021, closing a stake of 897 shares — an estimated $220K sold.

QCM Cayman first reported a position in BIIB in Q4 2013 and held it in 7 quarters. The position peaked at $726K in Q3 2015. 1,094 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

QCM Cayman reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
QCM Cayman sold 897 Biogen shares in Q1 2021, an estimated $220K.
QCM Cayman first reported a position in Biogen in Q4 2013 and held it in 7 quarters.
QCM Cayman's Biogen position peaked at $726K in Q3 2015.
1,094 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on QCM Cayman's 13F filing for Q1 2021, filed 17 May 2021.